Biogen presented new 76-week data on EMPAVELI (pegcetacoplan) at the ASN Kidney Week 2026, demonstrating sustained reduction in proteinuria and stabilization of kidney function in patients with rare kidney diseases C3G and primary IC-MPGN. This supports EMPAVELI's expanded FDA indication as the first therapy approved to reduce both proteinuria and kidney function loss in these conditions. Biogen also highlighted investigational drug felzartamab, targeting immune-mediated kidney diseases, with ongoing Phase 3 trials and data expected in 2027. These developments address significant unmet needs in nephrology and transplant care, with multiple presentations and posters shared at the conference.
As of Oct 19, 2026 18:12 WIB, Biogen Inc (BIIB) shares trade at USD 232.38 on Pluang, showing a slight decrease of 0.12% over the day. The stock's market capitalization stands at $34.37 billion, reflecting its significant presence in the health sector. This trading data provides context to Biogen's ongoing advancements in nephrology treatments presented at the ASN Kidney Week 2026.
